Patents Assigned to Pharmacyclics, Inc.
  • INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS
    Publication number: 20140079690
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: August 12, 2013
    Publication date: March 20, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. BUGGY, Laurence ELIAS
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140080844
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Application
    Filed: November 20, 2013
    Publication date: March 20, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Wei CHEN, David J. LOURY, Tarak D. MODY, Erik VERNER, Mark Stephen SMYTH, Wenchen LUO
  • FACTOR VIIA INHIBITOR
    Publication number: 20140080879
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: PHARMACYCLICS, INC.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8663961
    Abstract: Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: May 15, 2012
    Date of Patent: March 4, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140057907
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase.
    Type: Application
    Filed: October 31, 2013
    Publication date: February 27, 2014
    Applicant: PHARMACYCLICS, INC.
    Inventors: Lee HONIGBERG, Erik Verner, Joseph J. Buggy, David Loury, Wei Chen
  • FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF
    Publication number: 20140057862
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Application
    Filed: October 31, 2013
    Publication date: February 27, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: David J. LOURY, Joseph J. BUGGY, Tarak D. MODY, Erik J. VERNER, Norbert PURRO, Sriram Balasubramanian
  • Inhibitors of Bruton's tyrosine kinase
    Patent number: 8658653
    Abstract: Disclosed herein are compounds, including compounds having the structure of Formula (A), (B), (C), and (D), as described in further detail herein, that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: February 25, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20140039186
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 26, 2013
    Publication date: February 6, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • MANUFACTURE, COMPOSITIONS AND USES OF COAGULATION FACTOR VIIA MODULATOR
    Publication number: 20140039022
    Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I:
    Type: Application
    Filed: October 8, 2013
    Publication date: February 6, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: David LOURY, Norbert PURRO
  • SELECTIVE INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20140004174
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Application
    Filed: May 20, 2013
    Publication date: January 2, 2014
    Applicant: Pharmacyclics, Inc.
    Inventors: Erik VERNER, Sriram BALASUBRAMANIAN, Joseph J. BUGGY
  • CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
    Publication number: 20130338172
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: June 3, 2013
    Publication date: December 19, 2013
    Applicant: Pharmacyclics, Inc.
    Inventors: Mark Smyth, Erick Goldman, David D. Wirth, Norbert Purro
  • Formulations of histone deacetylase inhibitor and uses thereof
    Patent number: 8603521
    Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: December 10, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: David J. Loury, Joseph J. Buggy, Tarak D. Mody, Erik J. Verner, Norbert Purro, Sriram Balasubramanian
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20130310402
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: April 24, 2013
    Publication date: November 21, 2013
    Applicant: PHARMACYCLICS, INC.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Inhibitors of bruton's tyrosine kinase
    Patent number: 8563563
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: October 22, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20130273030
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: January 22, 2013
    Publication date: October 17, 2013
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Manufacture, compositions and uses of coagulation factor VIIa modulator
    Patent number: 8552046
    Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: October 8, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: David Loury, Norbert Purro
  • Inhibitors of Bruton'S tyrosine kinase
    Patent number: 8552010
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: October 8, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • BRUTON'S TYROSINIE KINASE ACTIVITY PROBE AND METHOD OF USING
    Publication number: 20130225812
    Abstract: Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use.
    Type: Application
    Filed: April 3, 2013
    Publication date: August 29, 2013
    Applicant: Pharmacyclics, Inc.
    Inventor: Pharmacyclics, Inc.
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20130202611
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: January 8, 2013
    Publication date: August 8, 2013
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Purinone compounds as kinase inhibitors
    Patent number: 8501724
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: April 30, 2012
    Date of Patent: August 6, 2013
    Assignee: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury